Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus- An Analysis from the UK NHS Perspective
Abstract
Authors
M Charokopou L Chuang B Verheggen D Gibson S Grandy B Kartman